Mol Pharm. 2023 Jan 2;20(1):582-592. doi: 10.1021/acs.molpharmaceut.2c00815. Epub 2022 Dec 14. ABSTRACT In this study, we investigated convection-enhanced delivery (CED) of 23 ± 3 nm gold nanoparticles (AuNPs) labeled with the β-particle-emitting radionuclide 177Lu (177Lu-AuNPs) for treatment of orthotopic U251-Luc…
The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors
Nucl Med Commun. 2022 Jan 1;43(1):73-77. doi: 10.1097/MNM.0000000000001488. ABSTRACT PURPOSE: To determine in a group of patients with progressive metastatic neuroendocrine tumors (PM-NETs) treated with 177Lu-DOTATATE whether a correlation exists between somatostatin receptor (SSTR)-2 expression in various tumors on baseline…
The role of [18F]-DCFPyL PET/MRI radiomics for pathological grade group prediction in prostate cancer
Eur J Nucl Med Mol Imaging. 2023 Feb 21. doi: 10.1007/s00259-023-06136-0. Online ahead of print. ABSTRACT PURPOSE: To evaluate the diagnostic accuracy of -DCFPyL PET/MRI radiomics for the prediction of pathological grade group in prostate cancer (PCa) in therapy-naïve patients.…
The role of [18F]-DCFPyL PET/MRI radiomics for pathological grade group prediction in prostate cancer
Eur J Nucl Med Mol Imaging. 2023 Feb 21. doi: 10.1007/s00259-023-06136-0. Online ahead of print. ABSTRACT PURPOSE: To evaluate the diagnostic accuracy of -DCFPyL PET/MRI radiomics for the prediction of pathological grade group in prostate cancer (PCa) in therapy-naïve patients.…
18F-DCFPyL PET/CT in advanced high-grade epithelial ovarian cancer: A prospective pilot study
Front Oncol. 2022 Oct 13;12:1025475. doi: 10.3389/fonc.2022.1025475. eCollection 2022. ABSTRACT OBJECTIVES: Glutamate carboxypeptidase-II (GCP-II), a zinc metalloenzyme that resides in cell membrane, has been reported as overexpressed in the neovasculature of ovarian cancers. The study objective was to determine whether…
18F-DCFPyL PET/CT in advanced high-grade epithelial ovarian cancer: A prospective pilot study
Front Oncol. 2022 Oct 13;12:1025475. doi: 10.3389/fonc.2022.1025475. eCollection 2022. ABSTRACT OBJECTIVES: Glutamate carboxypeptidase-II (GCP-II), a zinc metalloenzyme that resides in cell membrane, has been reported as overexpressed in the neovasculature of ovarian cancers. The study objective was to determine whether…
Extended Results and Independent Validation of a Phase 2 Trial of Metastasis Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer
Int J Radiat Oncol Biol Phys. 2022 Aug 25:S0360-3016(22)00644-7. doi: 10.1016/j.ijrobp.2022.06.080. Online ahead of print. ABSTRACT PURPOSE: The role of metastasis-directed therapy (MDT) in molecularly defined oligorecurrent prostate cancer (PCa) remains irresolute. We present extended follow-up and an independent validation…
Current and future strategies for radiation therapy in gastric cancer
J Surg Oncol. 2022 Jun;125(7):1161-1175. doi: 10.1002/jso.26880. ABSTRACT Gastric cancers are heterogeneous. There are important differences between gastric and junctional tumors and a focus on evidence based on true gastric cancers is important to guide treatment decision and the design…
Neuroendocrine Tumors: Imaging Perspective
PET Clin. 2021 Jul;16(3):353-364. doi: 10.1016/j.cpet.2021.03.002. ABSTRACT This article summarizes the role of PET imaging for detection, characterization, and theranostic/therapy planning for neuroendocrine tumors. Topics in this article span overall imaging accuracy with mostly 68Ga-DOTA-peptide imaging as well as basic…
Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
J Nucl Med. 2021 Oct;62(10):1406-1414. doi: 10.2967/jnumed.120.256727. Epub 2021 Feb 12. ABSTRACT The aim of this study was to determine whether quantitative PET parameters on baseline 68Ga-DOTATATE PET/CT and interim PET (iPET) performed before the second cycle of therapy are…